Functional effects and molecular mechanisms of subtype-selective ERalpha and ERbeta agonists in the cardiovascular system.
Gender differences in the development of cardiovascular disease suggested for a protective function of estrogens in heart disease. The negative or neutral outcome of clinical trials on hormone replacement therapy provides clear evidence that the role of female sex hormones in the cardiovascular system is more complex than previously thought. In particular, the function of estrogens can not be understood without detailed knowledge on the specific function of both estrogen receptor subtypes in the heart and in the vasculature. In here, we review recent studies on subtype selective ERalpha and ERbeta agonists in different animal models of hypertension, cardiac hypertrophy and vascular inflammation. The results indicate that the activation of specific ER subtypes confers specific as well as redundant protective effects in hypertensive heart disease that might ultimately translate into novel treatment options for hypertensive heart disease.
Arias-Loza
P A
PA
Medizinische Klinik I, University of Würzburg, Josef-Schneider Str. 2, 97080 Würzburg, Germany.
Jazbutyte
V
V
Fritzemeier
K H
KH
Hegele-Hartung
C
C
Neyses
L
L
Ertl
G
G
Pelzer
T
T
D000818:Animals; D006332:Cardiomegaly / Q000188:drug therapy; D002319:Cardiovascular System / Q000187:drug effects*; D047628:Estrogen Receptor alpha / Q000819:agonists* / Q000502:physiology; D047629:Estrogen Receptor beta / Q000819:agonists* / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D051381:Rats; D011918:Rats, Inbred SHR; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology*